This early-stage study is testing a new cell-based immunotherapy called ACIT-1 in adults with cancer. The main goals are to find the safest dose and see if the treatment can help the patient's own immune system recognize and attack cancer cells. About half of the participants wil…
Phase: PHASE1, PHASE2 • Sponsor: Cancer Vaccines Limited • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC